Tygacil(tigecycline)
Tigecycline, Tygacil (tigecycline) is a small molecule pharmaceutical. Tigecycline was first approved as Tygacil on 2005-06-15. It is used to treat bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial skin diseases, infectious skin diseases, intraabdominal infections, and soft tissue infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Tygacil (generic drugs available since 2015-05-27)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tigecycline
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TIGECYCLINE | Accord Healthcare | N-208744 RX | 2018-01-18 | 1 products |
| TIGECYCLINE | Amneal Pharmaceuticals | N-211158 RX | 2018-08-02 | 1 products |
| TIGECYCLINE | Fresenius Kabi | N-205645 RX | 2016-12-01 | 1 products, RLD, RS |
| TYGACIL | CV Sciences | N-021821 RX | 2005-06-15 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tigecycline | ANDA | 2024-10-01 |
| tygacil | New Drug Application | 2023-04-20 |
Indications
FDA
EMA
Show 5 more
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
79 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 4 | 16 | 10 | 12 | 40 |
| Communicable diseases | D003141 | — | — | — | 3 | 12 | 9 | 6 | 29 |
| Intraabdominal infections | D059413 | — | — | — | 2 | 5 | 5 | 4 | 15 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 1 | 6 | 3 | 1 | 12 |
| Skin diseases | D012871 | — | L00-L99 | — | 2 | 2 | 2 | 2 | 8 |
| Infectious skin diseases | D012874 | — | — | — | 2 | 1 | 1 | 3 | 7 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | 2 | 3 | 2 | 1 | 6 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | 1 | 1 | 1 | 2 | 2 | 6 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | 2 | 2 | 4 |
| Cross infection | D003428 | — | — | — | — | 3 | 1 | — | 4 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 2 | 6 | — | 1 | 9 |
| Bacterial infections | D001424 | — | A49 | — | 1 | 5 | — | 3 | 9 |
| Community-acquired infections | D017714 | — | — | — | — | 2 | — | 2 | 4 |
| Enterobacteriaceae infections | D004756 | EFO_1001313 | — | — | 1 | 1 | — | 2 | 3 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 2 | 1 | — | — | 2 |
| Gram-positive bacterial infections | D016908 | — | — | — | — | 2 | — | — | 2 |
| Surgical wound infection | D013530 | — | — | — | — | 1 | — | — | 1 |
| Diabetic foot | D017719 | EFO_1001459 | — | — | — | 1 | — | — | 1 |
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | 1 | — | — | 1 |
| Emergencies | D004630 | — | — | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | 1 | — | — | — | 1 |
| Cellulitis | D002481 | EFO_0003035 | L03.90 | — | 1 | — | — | — | 1 |
| Mycobacterium abscessus | D000073358 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | 1 | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
| Fibrosis | D005355 | — | — | 1 | — | — | — | — | 1 |
| Biliary liver cirrhosis | D008105 | — | K74.3 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inappropriate prescribing | D057970 | — | — | — | — | — | — | 1 | 1 |
| Acinetobacter infections | D000151 | EFO_1000792 | — | — | — | — | — | 1 | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | — | — | — | 1 | 1 |
| Extracorporeal membrane oxygenation | D015199 | — | — | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | — | — | — | — | 1 | 1 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Clostridium infections | D003015 | EFO_1000874 | A05.2 | — | — | — | — | 1 | 1 |
| Clostridioides difficile | D016360 | NCBITaxon_1496 | — | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tigecycline |
| INN | tigecycline |
| Description | Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
|
| Classification | Small molecule |
| Drug class | antibiotics (tetracycline derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)c1cc(NC(=O)CNC(C)(C)C)c(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O |
Identifiers
| PDB | — |
| CAS-ID | 220620-09-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL376140 |
| ChEBI ID | 149836 |
| PubChem CID | 5282044 |
| DrugBank | DB00560 |
| UNII ID | 70JE2N95KR (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Tygacil – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,929 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tigecycline, Tygacil
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,162 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use